Reports Q4 revenue $30M, consensus $28.34M. Joe Todisco, CorMedix (CRMD) CEO, commented, “I am proud of the Company’s recent progress as we execute on our launch objectives and increase patient access to DefenCath across settings of care. We have seen continued growth from existing customers throughout the first quarter and we are focused on growing our patient base in 2025 with both existing and new accounts.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRMD:
- Cormedix: Buy Rating Affirmed Amid Growth Potential and Strategic LDO Partnerships
- Morning Movers: Mobileye jumps following Volkswagen ADAS partnership
- Cormedix: Positive Outlook with Strategic Advancements and Strong Financial Performance
- Options Volatility and Implied Earnings Moves Today, March 25, 2025
- Options Volatility and Implied Earnings Moves This Week, March 24 – March 27, 2025